On July 24, CSPC PHARMA rose 3.23% in regular trading, trading at HKD 8.66/share, with turnover of HKD 182 million.

On the news front, the company announced on July 22 that its SYS 6026 injection, a therapeutic mRNA vaccine for treating HPV16 or HPV18-related cervical high-grade squamous intraepithelial lesions, has officially commenced a Phase II clinical trial in China. SYS 6026 is classified as a Category 1 therapeutic biological product, targeting E6 and E7 proteins of HPV16 and HPV18 subtypes. The company had previously received clinical trial approval from China's National Medical Products Administration in November 2024 and has already initiated a Phase I trial evaluating safety and tolerability, with subject recruitment and screening currently underway.

This milestone adds to CSPC PHARMA's recent pipeline momentum, which includes a USD 1.77 billion strategic siRNA collaboration with AstraZeneca announced in early July, a breakthrough therapy designation for SYS6043 in platinum-resistant ovarian cancer, and the Phase II initiation of SYH2070 for mixed hyperlipidaemia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)